ABOUT US
About HLB
Greeting
History
Location
GROUP
Pharma·Bio
Ship ·Plant ·Energy
Life · Health · Leisure
Finance
BUSINESS
Pharma·Bio
cytotoxic antineoplastic drug
targeted therapy
immunotherapy
Healthcare
Special ship
ESG
EHS
EHS경영
친환경 제품 및 서비스
인증 및 수상
CSR
Human resources
인재육성 제도
복리후생
직원안전 및 보건
핵심고용지표
Governance
주주
이사회
정관
기타
Initiative
ESG Report
IR
Stock Index
Official Notice
PR
Press
Library
CAREERS
Recruiting
ENG
Korean
English
home
Title + Content
Title+Content
Title
Content
Search
Number
Title
Author
Date
16
Acquisition of Riovceranib’s global rights
admin
2020.02.27
15
Additional update about the investment in Immunomic Therapeutics
admin
2020.02.25
14
Overview of Immunomic Therapeutics, Inc.
admin
2020.02.21
13
Elevar to Establish 'Neolevar' and to participate in JP Morgan Healthcare (1/6/2020)
admin
2020.01.06
12
ESMO Asia 2019 takes place in Singapore (11/20/2019)
admin
2019.12.09
11
A researcher announces clinical outcome of Rivoceranib Cervical Cancer (11/15/2019)
admin
2019.12.09
10
Contents related to Rivoceranib's Major Anti-Cancer Mechanism (11/13/2019)
admin
2019.12.09
9
Promethera announces Clinical Phase 2a of HepaStem at AASLD (11/11/2019)
admin
2019.12.03
8
A researcher announces clinical outcome of “Rivoceranib+TACE” combination study (11/11/2019)
admin
2019.12.03
7
Rivoceranib listed on the Scientific Reports (11/11/2019)
admin
2019.12.03
1
2
3